secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-10-18T23:59:59+00:00
Accession:  0001558370-24-013387
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CHMP maintains negative opinion on PTC's Translarna renewal; EC decision awaited in ~67 days
--------------------------------------------------------------------------------

- CHMP upheld negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) in nmDMD after re-examination.
- European Commission expected to decide on opinion adoption in approximately 67 days; Translarna remains authorized pending EC review.
- CEO cites totality of evidence from three placebo-controlled trials and STRIDE registry as supportive of continued authorization.
- CHMP based decision on primary analysis subpopulation of Study 041; PTC will provide all possible evidence to EC for continued authorization.
- Translarna currently authorized in Europe; PTC continues to ensure availability for nmDMD patients during review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024013387/0001558370-24-013387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024013387/tmb-20241018x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer